Northwestern University
Feinberg School of Medicine
Grazia Aleppo is a Professor of Medicine at the Feinberg School of Medicine, Northwestern University in Chicago, IL. She is the medical director of Northwestern Medicine Diabetes Training and Education Program and the Associate Chief for Clinical Affairs in the division of Endocrinology, Metabolism and Molecular Medicine at Northwestern. Dr. Aleppo’s clinical interest and research focus on diabetes and the use of technology. She has been recognized as an educator and has received multiple teaching awards at Northwestern University. Her research focus in on diabetes and the use of technology, such as insulin pumps and CGM therapy, as well as the implementation of use of hybrid-closed loop insulin pump technology in clinical practice. She has published in many peer reviewed journals on the use of CGM and insulin pump therapy in clinical practice.

Presenter of 3 Presentations

Q&A (ID 1115)

Lecture Time
08:45 - 08:50
Session Type
INDUSTRY
Date
Fri, 24.02.2023
Session Time
08:00 - 08:50
Room
Hall A3

Are technology guidelines outpacing CGM adoption for type 2 diabetes in clinical practice? (ID 1113)

Lecture Time
08:10 - 08:25
Session Type
INDUSTRY
Date
Fri, 24.02.2023
Session Time
08:00 - 08:50
Room
Hall A3

OP084 - VIRTUAL DIABETES SPECIALTY CARE – INDIVIDUALIZED TELEMEDICINE AND TECHNOLOGY SUPPORT (ID 336)

Lecture Time
16:56 - 17:04
Session Type
ORAL PRESENTATIONS SESSION
Date
Fri, 24.02.2023
Session Time
16:40 - 18:10
Room
Hall M1

Abstract

Background and Aims

The feasibility and efficacy of establishing a comprehensive care virtual diabetes clinic model including initiation and support for continuous glucose monitor (CGM) use was examined.

Methods

234 adults ≥18 years old with type 1 diabetes (T1D; N=160) or type 2 diabetes (T2D, N=74) using basal-bolus insulin (73 pump, 161 multiple daily insulin injections) were assigned a certified diabetes care and education specialist to provide telehealth support including remote CGM training. Participants not using a Dexcom G6 CGM (N=187) at enrollment were provided a Dexcom G6; current users (N=47) continued use. Participants were followed for 6 months to assess CGM use, glycemic and quality of life outcomes.

Results

Mean HbA1c reduction from baseline to 6 months was 0.6% (P<0.001)(T1D) and 1.0% (P<0.001)(T2D). Mean glucose decreased from 183mg/dL to 165mg/dL (T1D) and 199mg/dL to 166mg/dL (T2D). Over 6 months, mean% time in range 70-180 mg/dL increased from 50% at baseline to 61% (T1D) and 48% to 66% (T2D); median use of CGM was 96% (T1D) and 94% (T2D). Glycemic outcomes improvements were observed in both current CGM users and those initiating CGM. Surveys indicated substantial benefit of CGM with reduced diabetes distress, and increased glucose monitoring satisfaction.

attd23-vdisc figure.png

Conclusions

Virtual clinic support was successful in achieving sustained CGM use and improved glycemic and quality of life outcomes. This approach could substantially increase CGM adoption by people with diabetes using insulin and improve outcomes among current CGM users by eliminating barriers such as geography and access to specialty care.

Hide